Hong Kong stock market anomaly | China Resources Pharmaceutical Group Limited -B (02171.HK) rises by more than 4% again, the company plans to repurchase no more than 1% of its own shares. CT041 is expected to submit a New Drug Application in the first half of the year.
According to the Wise Finance and Economics App, Kollix Pharmaceuticals -B (02171.HK) has risen by over 4% again, as of the time of publication, it has increased by 4.36%, to 19.14 Hong Kong dollars, with a turnover of 35.8458 million Hong Kong dollars.
Latest
